Roberto Filomia
Overview
Explore the profile of Roberto Filomia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franze M, Saitta C, Lombardo D, Musolino C, Caccamo G, Filomia R, et al.
Clin Res Hepatol Gastroenterol
. 2025 Mar;
49(4):102566.
PMID: 40043798
Introduction And Objectives: Identifying hepatitis B virus (HBV) patients eligible for safe nucleos(t)ide analogues (NAs) discontinuation remains challenging. Discrepant data on combined HBV DNA and quantitative HBV surface antigen (qHBsAg)...
2.
Granese R, Calagna G, Alibrandi A, Martinelli C, Romeo P, Filomia R, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445442
The aims of our study were to evaluate the maternal and fetal outcomes of intrahepatic cholestasis of pregnancy (ICP). In this observational, retrospective case-control study, we included all pregnant women...
3.
Franze M, Filomia R, Caccamo G, Pitrone C, Alibrandi A, Saitta C, et al.
J Pers Med
. 2022 Dec;
12(11).
PMID: 36579534
The predictive factors of long-term clinical benefits in patients with hepatitis C virus (HCV)—related liver cirrhosis after Direct Antiviral Agents (DAA) treatment are still undefined. The aim of this study...
4.
Calvaruso V, Celsa C, DAmbrosio R, Simone F, Petta S, Cacciola I, et al.
Am J Gastroenterol
. 2022 Aug;
117(11):1816-1824.
PMID: 35973181
Introduction: Noninvasive criteria to predict the progression of low-risk esophageal varices (EV) in patients with compensated hepatitis C virus (HCV) cirrhosis after sustained virological response (SVR) by direct-acting antivirals (DAAs)...
5.
Saitta C, Caruso A, Maimone S, Filomia R, Cacciola I, Caccamo G, et al.
Intern Emerg Med
. 2022 Mar;
17(6):1609-1616.
PMID: 35332431
Insufficient information is available about co-factors favoring the progression of non-alcoholic fatty liver disease (NAFLD) toward cirrhosis. We aimed to evaluate the impact of a limited alcohol intake and of...
6.
Kondili L, Monti M, Quaranta M, Gragnani L, Panetta V, Brancaccio G, et al.
Hepatology
. 2021 Dec;
76(1):220-232.
PMID: 34919289
Background And Aims: Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over...
7.
Caccamo G, Franze M, Saffioti F, Pitrone C, Porcari S, Alibrandi A, et al.
Dig Dis Sci
. 2021 May;
67(6):2655-2665.
PMID: 34041650
Background: The negative clinical impact of bacterial infections (BI) in patients with cirrhosis is well documented. In cirrhotic patients, failure to isolate the pathogen is a frequent event, occurring in...
8.
Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, et al.
Liver Int
. 2021 Apr;
41(9):2059-2067.
PMID: 33894103
Background: Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of...
9.
Quaranta M, Ferrigno L, Monti M, Filomia R, Biliotti E, Iannone A, et al.
Hepatol Int
. 2020 Apr;
14(3):362-372.
PMID: 32279177
Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated. Methods: Patients...
10.
Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, et al.
J Hepatol
. 2020 Apr;
73(3):593-602.
PMID: 32243959
Background & Aim: An unexpected early increase in incidence, recurrence and clinical aggressiveness of hepatocellular carcinoma (HCC) has been reported (and refuted) in patients with HCV-related cirrhosis following direct-acting antiviral...